ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.
The grade B recommendation (moderate certainty) targets youth aged 6 years and older with a BMI at or above the 95th percentile for age and sex.
Three falsified batches of semaglutide (Ozempic) are in circulation, posing risks for ineffective treatment due to incorrect dosing, contamination, and use of unknown ingredients, warned WHO.
Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.
For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.
Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.
In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.